281 related articles for article (PubMed ID: 17034418)
1. Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors.
Alexandrescu DT; Vaillant JG; Dasanu CA
Clin Exp Dermatol; 2007 Jan; 32(1):71-4. PubMed ID: 17034418
[TBL] [Abstract][Full Text] [Related]
2. Facial acneiform rash associated with sorafenib.
Fleta-Asín B; Vañó-Galván S; Ledo-Rodríguez A; Truchuelo-Díez M; Jaén-Olasolo P
Dermatol Online J; 2009 Apr; 15(4):7. PubMed ID: 19450400
[TBL] [Abstract][Full Text] [Related]
3. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Shin JU; Park JH; Cho BC; Lee JH
Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous side-effects of EGFR inhibitors and their management.
Ehmann LM; Ruzicka T; Wollenberg A
Skin Therapy Lett; 2011 Jan; 16(1):1-3. PubMed ID: 21293833
[TBL] [Abstract][Full Text] [Related]
5. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
[TBL] [Abstract][Full Text] [Related]
6. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
7. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
[TBL] [Abstract][Full Text] [Related]
8. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Requena C; Llombart B; Sanmartín O
Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
10. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
Tan EH; Chan A
Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
[TBL] [Abstract][Full Text] [Related]
11. Biology of interactions: antiepidermal growth factor receptor agents.
Harari PM; Allen GW; Bonner JA
J Clin Oncol; 2007 Sep; 25(26):4057-65. PubMed ID: 17827454
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous drug eruptions induced by sorafenib: a case series.
Maddox JS; Kung EF; Petronic-Rosic V; Sethi A
J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
[TBL] [Abstract][Full Text] [Related]
13. [Erlotinib-induced acneiform rash not affecting previously irradiated skin].
Eguren C; Domínguez-Fernández I; Santiago-Sánchez-Mateos DI; García-Díez A
Actas Dermosifiliogr; 2010 Mar; 101(2):186-7. PubMed ID: 20223168
[No Abstract] [Full Text] [Related]
14. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
Treudler R; Zouboulis CC
Dermatology; 2005; 211(4):375-6. PubMed ID: 16286753
[No Abstract] [Full Text] [Related]
15. Grover's disease induced by cetuximab.
Tscharner GG; Bühler S; Borner M; Hunziker T
Dermatology; 2006; 213(1):37-9. PubMed ID: 16778425
[TBL] [Abstract][Full Text] [Related]
16. Clinical approaches to minimize rash associated with EGFR inhibitors.
Oishi K
Oncol Nurs Forum; 2008 Jan; 35(1):103-11. PubMed ID: 18192159
[TBL] [Abstract][Full Text] [Related]
17. Common side effects of anti-EGFR therapy: acneform rash.
Sipples R
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
[TBL] [Abstract][Full Text] [Related]
18. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
19. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
[TBL] [Abstract][Full Text] [Related]
20. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition.
Wollenberg A; Moosmann N; Klein E; Katzer K
Exp Dermatol; 2008 Sep; 17(9):790-2. PubMed ID: 18503553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]